PennyStock101

ACER THERAPEUTICS await FDA verdict June 25th

NASDAQ:ACER   Acer Therapeutics Inc
Investors eagerly await the FDA verdict on its NDA for Edviso, which is being evaluated for the treatment of vascular Ehlers -Danlos syndrome in patients with a confirmed type 111 collagen mutation. This for sure will be a market moving event.

AVERAGE ANALYSTS PRICE TARGET $51. 40
AVERAGE RECOMMENDATION BUY

COMPANY PROFILE
Acer Therapeutics , Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling in September 2017 and is headquartered in Newton, MA.

Your Intro To Penny Stock Trading Success...

1) Sign Up for our 100% Free Email Newsletter:
http://www.PennyStock101.org

2) Follow our Telegram Channel @ https://t.me/PennyStock101

3) Join our LIVE CHAT on Discord @ https://discord.gg/qSVhafy
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.